Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Sold by Vanguard Group Inc.

Vanguard Group Inc. decreased its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 1.8% during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 9,941,887 shares of the company's stock after selling 177,754 shares during the period. Vanguard Group Inc. owned approximately 10.05% of Neurocrine Biosciences worth $1,099,573,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also bought and sold shares of the company. Dodge & Cox grew its holdings in shares of Neurocrine Biosciences by 134.2% in the fourth quarter. Dodge & Cox now owns 3,016,425 shares of the company's stock worth $411,742,000 after purchasing an additional 1,728,605 shares during the last quarter. Orbimed Advisors LLC grew its holdings in shares of Neurocrine Biosciences by 210.4% in the fourth quarter. Orbimed Advisors LLC now owns 938,120 shares of the company's stock worth $128,053,000 after purchasing an additional 635,900 shares during the last quarter. Assenagon Asset Management S.A. lifted its stake in Neurocrine Biosciences by 1,405.2% in the first quarter. Assenagon Asset Management S.A. now owns 393,455 shares of the company's stock worth $43,516,000 after acquiring an additional 367,315 shares during the period. Iron Triangle Partners LP purchased a new stake in Neurocrine Biosciences in the fourth quarter worth about $43,434,000. Finally, Alyeska Investment Group L.P. purchased a new stake in Neurocrine Biosciences in the fourth quarter worth about $33,979,000. Institutional investors own 92.59% of the company's stock.

Insider Transactions at Neurocrine Biosciences

In other news, Director Kevin Charles Gorman sold 106,322 shares of the firm's stock in a transaction that occurred on Thursday, August 7th. The shares were sold at an average price of $126.41, for a total transaction of $13,440,164.02. Following the sale, the director owned 514,596 shares of the company's stock, valued at $65,050,080.36. This trade represents a 17.12% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Jude Onyia sold 59,819 shares of Neurocrine Biosciences stock in a transaction on Wednesday, July 9th. The shares were sold at an average price of $130.46, for a total transaction of $7,803,986.74. Following the completion of the sale, the insider directly owned 18,289 shares in the company, valued at $2,385,982.94. This represents a 76.58% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 196,573 shares of company stock valued at $25,112,766 in the last 90 days. 4.80% of the stock is currently owned by company insiders.

Neurocrine Biosciences Price Performance

NASDAQ:NBIX traded up $0.52 during midday trading on Friday, hitting $131.83. The company's stock had a trading volume of 72,313 shares, compared to its average volume of 1,274,907. The firm has a market cap of $13.07 billion, a P/E ratio of 38.98, a P/E/G ratio of 0.95 and a beta of 0.25. Neurocrine Biosciences, Inc. has a fifty-two week low of $84.23 and a fifty-two week high of $154.87. The firm's 50 day moving average is $129.06 and its 200-day moving average is $119.95.

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last issued its quarterly earnings data on Wednesday, July 30th. The company reported $1.06 EPS for the quarter, topping analysts' consensus estimates of $0.98 by $0.08. The business had revenue of $687.50 million for the quarter, compared to analysts' expectations of $653.09 million. Neurocrine Biosciences had a net margin of 13.88% and a return on equity of 13.22%. The business's revenue was up 16.5% on a year-over-year basis. During the same quarter last year, the company earned $1.63 EPS. As a group, analysts forecast that Neurocrine Biosciences, Inc. will post 4.28 EPS for the current year.

Analysts Set New Price Targets

A number of analysts recently weighed in on NBIX shares. Evercore ISI lowered their price objective on shares of Neurocrine Biosciences from $190.00 to $185.00 and set an "outperform" rating for the company in a research note on Thursday, April 24th. Wedbush increased their price target on shares of Neurocrine Biosciences from $137.00 to $141.00 and gave the company an "outperform" rating in a research report on Thursday, July 31st. Guggenheim increased their price target on shares of Neurocrine Biosciences from $165.00 to $175.00 and gave the company a "buy" rating in a research report on Friday, August 1st. Wall Street Zen raised shares of Neurocrine Biosciences from a "hold" rating to a "strong-buy" rating in a research report on Saturday, August 2nd. Finally, Canaccord Genuity Group increased their price target on shares of Neurocrine Biosciences from $158.00 to $160.00 and gave the company a "buy" rating in a research report on Tuesday, May 6th. Three analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Neurocrine Biosciences presently has a consensus rating of "Moderate Buy" and an average price target of $160.90.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.